Preliminary Fourth Quarter and Full Year 2022 Highlights:
- Preliminary unaudited revenue for the fourth quarter of 2022 is expected to be between
$107.0 million and$108.0 million , up 12% sequentially and 29% year-over-year (at the midpoint of the range). - Preliminary unaudited revenue for the full year 2022 is expected to be between
$382.7 million and$383.7 million , up approximately 38% over the full year 2021 (at the midpoint of the range). - Ended 2022 with over 275 U.S. sales territories.
“Our fourth quarter was successful and highly productive. We executed crisply across all five of our growth drivers and generated robust revenue growth,” said
The preliminary unaudited revenue results described in this press release are estimates only and subject to revision, including as a result of completion of customary annual audit procedures, until Inari reports its full financial results for the fourth quarter and full year 2022 in our Annual Report on Form 10-K.
Full Year 2023 Revenue Guidance
Inari is providing financial guidance for full year 2023 revenue of
About
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of
Forward Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated fourth quarter and full year 2022 revenue and sales territories and expected full year 2023 revenue, and are based on Inari’s current expectations, forecasts, and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended
Investor Contact:
ICR Westwicke
Phone +1-415-202-5678
caroline.corner@westwicke.com
![](https://ml.globenewswire.com/media/NjZkOTk2MTEtOWRiZC00ZGI0LWJlYmMtMTM5ZDU4ODNiOTgwLTEyMDYwNjY=/tiny/Inari-Medical-Inc-.png)
2023 GlobeNewswire, Inc., source